Short answer
FATE THERAPEUTICS INC (FATE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$31M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY · −100.0% QoQ
- Net income
- −$31M
- +4.8% YoY · −1.8% QoQ
- EPS (diluted)
- −$0.25
- +7.4% YoY · +0.0% QoQ
Source: XBRL data from the FATE THERAPEUTICS INC (FATE) Q3 2026 10-Q on SEC EDGAR. USD.
FATE THERAPEUTICS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly collaboration revenue $0 vs $1.7M YoY, following Ono performance-obligation completion
- R&D expense $24.2M vs $25.8M YoY, G&A expense $8.0M vs $10.6M
- Best-performing area: clinical trials, expense increase $2.4M YoY; laboratory materials expense decrease $1.5M
- Cash, cash equivalents and short-term investments $139.1M; operating cash used $82.1M
- Outlook: funding sufficient for at least twelve months; $15.0M CIRM grant pending agreement and milestones, additional capital expected sep
Risk Factors
- Newly added clinical-operations risk triggered by September 2026 CAR-T trial suspensions after fatal immune effector cell-associated hemophagocytic syndrome cases
- Most materially updated regulatory risk: RECLAIM-LN Phase 2 design may require additional patients, trials, or safety data before FT819 approval
- Manufacturing compliance risk: FDA CDRP participation may not accelerate FT819 development or manufacturing readiness
- Operational risk: limited investigator CAR-T experience could cause delayed adverse-event recognition and inconsistent safety reporting
- Competitive risk: increased autoimmune cell-therapy trials are intensifying competition for eligible patients and investigators
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FATE THERAPEUTICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.